King Wealth Management Group Decreases Stock Holdings in Teva Pharmaceutical Industries Ltd. $TEVA

King Wealth Management Group trimmed its position in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 15.6% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 135,000 shares of the company’s stock after selling 25,000 shares during the period. King Wealth Management Group’s holdings in Teva Pharmaceutical Industries were worth $4,213,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Phoenix Financial Ltd. lifted its position in shares of Teva Pharmaceutical Industries by 9.4% during the third quarter. Phoenix Financial Ltd. now owns 41,295,244 shares of the company’s stock valued at $834,164,000 after buying an additional 3,533,800 shares during the last quarter. National Pension Service boosted its stake in Teva Pharmaceutical Industries by 24.2% in the 3rd quarter. National Pension Service now owns 2,073,293 shares of the company’s stock worth $41,881,000 after purchasing an additional 404,526 shares in the last quarter. Public Sector Pension Investment Board boosted its stake in Teva Pharmaceutical Industries by 11.5% in the 3rd quarter. Public Sector Pension Investment Board now owns 670,467 shares of the company’s stock worth $13,543,000 after purchasing an additional 69,000 shares in the last quarter. Thrivent Financial for Lutherans acquired a new stake in Teva Pharmaceutical Industries in the 3rd quarter worth approximately $4,029,000. Finally, Menora Mivtachim Holdings LTD. boosted its stake in Teva Pharmaceutical Industries by 1.1% in the 3rd quarter. Menora Mivtachim Holdings LTD. now owns 38,920,294 shares of the company’s stock worth $786,190,000 after purchasing an additional 427,000 shares in the last quarter. 54.05% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

TEVA has been the subject of a number of recent analyst reports. Truist Financial lifted their target price on shares of Teva Pharmaceutical Industries from $42.00 to $45.00 and gave the stock a “buy” rating in a research note on Thursday, April 30th. Wall Street Zen cut shares of Teva Pharmaceutical Industries from a “strong-buy” rating to a “hold” rating in a research note on Saturday, May 2nd. Bank of America lifted their target price on shares of Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the stock a “buy” rating in a research note on Thursday, April 9th. UBS Group lifted their target price on shares of Teva Pharmaceutical Industries from $36.00 to $42.00 and gave the stock a “buy” rating in a research note on Thursday, April 30th. Finally, The Goldman Sachs Group lifted their target price on shares of Teva Pharmaceutical Industries from $36.00 to $45.00 and gave the stock a “buy” rating in a research note on Monday, February 9th. Nine research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $41.78.

Insider Activity at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, EVP Eliyahu Sharon Kalif sold 345,810 shares of the firm’s stock in a transaction that occurred on Thursday, February 26th. The shares were sold at an average price of $33.64, for a total transaction of $11,633,048.40. Following the completion of the transaction, the executive vice president directly owned 57,478 shares of the company’s stock, valued at approximately $1,933,559.92. This trade represents a 85.75% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Richard D. Francis sold 442,935 shares of the firm’s stock in a transaction that occurred on Tuesday, March 3rd. The stock was sold at an average price of $32.36, for a total transaction of $14,333,376.60. Following the transaction, the chief executive officer directly owned 642,099 shares of the company’s stock, valued at $20,778,323.64. This represents a 40.82% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 1,280,269 shares of company stock worth $42,755,980 in the last ninety days. 0.54% of the stock is owned by company insiders.

Teva Pharmaceutical Industries Stock Performance

TEVA opened at $34.66 on Wednesday. Teva Pharmaceutical Industries Ltd. has a 12-month low of $14.99 and a 12-month high of $37.35. The company has a current ratio of 1.01, a quick ratio of 0.78 and a debt-to-equity ratio of 1.70. The firm has a market capitalization of $39.85 billion, a PE ratio of 26.06, a P/E/G ratio of 3.29 and a beta of 0.86. The firm has a 50 day moving average of $32.05 and a two-hundred day moving average of $31.16.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings results on Tuesday, March 31st. The company reported $0.53 earnings per share (EPS) for the quarter. Teva Pharmaceutical Industries had a net margin of 9.01% and a return on equity of 43.53%. The company had revenue of $3.98 billion during the quarter. On average, analysts anticipate that Teva Pharmaceutical Industries Ltd. will post 2.49 EPS for the current year.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.